Literature DB >> 23802180

Glycoproteomic analysis of bronchoalveolar lavage (BAL) fluid identifies tumor-associated glycoproteins from lung adenocarcinoma.

Qing Kay Li1, Punit Shah, Yan Li, Paul O Aiyetan, Jing Chen, Rex Yung, Daniela Molena, Edward Gabrielson, Frederic Askin, Daniel W Chan, Hui Zhang.   

Abstract

Cytological examination of cells from bronchoalveolar lavage (BAL) is commonly used for the diagnosis of lung cancer. Proteins released from lung cancer cells into BAL may serve as biomarkers for cancer detection. In this study, N-glycoproteins in eight cases of BAL fluid, as well as eight lung adenocarcinoma tissues and eight tumor-matched normal lung tissues, were analyzed using the solid-phase extraction of N-glycoprotein (SPEG), iTRAQ labeling, and liquid chromatography tandem mass spectrometry (LC-MS/MS). Of 80 glycoproteins found in BAL specimens, 32 were identified in both cancer BAL and cancer tissues, with levels of 25 glycoproteins showing at least a 2-fold difference between cancer and benign BAL. Among them, eight glycoproteins showed greater than 2-fold elevations in cancer BAL, including Neutrophil elastase (NE), Integrin alpha-M, Cullin-4B, Napsin A, lysosome-associated membrane protein 2 (LAMP2), Cathepsin D, BPI fold-containing family B member 2, and Neutrophil gelatinase-associated lipocalin. The levels of Napsin A in cancer BAL were further verified in independently collected 39 BAL specimens using an ELISA assay. Our study demonstrates that potential protein biomarkers in BAL fluid can be detected and quantified.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23802180      PMCID: PMC4238415          DOI: 10.1021/pr400274w

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  43 in total

Review 1.  Application of glycoproteomics for the discovery of biomarkers in lung cancer.

Authors:  Qing Kay Li; Edward Gabrielson; Hui Zhang
Journal:  Proteomics Clin Appl       Date:  2012-06       Impact factor: 3.494

2.  Alpha-1-antitrypsin phenotypes and neutrophil elastase gene promoter polymorphisms in lung cancer.

Authors:  Aleksandra Topic; Mila Ljujic; Aleksandra Nikolic; Natasa Petrovic-Stanojevic; Vesna Dopudja-Pantic; Marija Mitic-Milikic; Dragica Radojkovic
Journal:  Pathol Oncol Res       Date:  2010-06-03       Impact factor: 3.201

3.  The cost of diagnosis: a comparison of four different strategies in the workup of solitary radiographic lung lesions.

Authors:  B Goldberg-Kahn; J C Healy; J W Bishop
Journal:  Chest       Date:  1997-04       Impact factor: 9.410

Review 4.  Proteome analysis of bronchoalveolar lavage in lung diseases.

Authors:  Barbara Magi; Elena Bargagli; Luca Bini; Paola Rottoli
Journal:  Proteomics       Date:  2006-12       Impact factor: 3.984

5.  Bronchoalveolar lavage fluid of lung cancer patients: mapping the uncharted waters using proteomics technology.

Authors:  Tonio Oumeraci; Bernd Schmidt; Thomas Wolf; Marc Zapatka; Andreas Pich; Benedikt Brors; Roland Eils; Michael Fleischhacker; Brigitte Schlegelberger; Nils von Neuhoff
Journal:  Lung Cancer       Date:  2011-02-18       Impact factor: 5.705

Review 6.  Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee.

Authors:  William D Travis
Journal:  Histopathology       Date:  2009-01       Impact factor: 5.087

7.  Local increase in polymorphonuclear leukocyte elastase is associated with tumor invasiveness in non-small cell lung cancer.

Authors:  J Yamashita; K Tashiro; S Yoneda; K Kawahara; T Shirakusa
Journal:  Chest       Date:  1996-05       Impact factor: 9.410

8.  Cytology of endobronchial ultrasound-guided transbronchial needle aspiration versus conventional transbronchial needle aspiration.

Authors:  Lisa Marie Stoll; Rex Chin Wei Yung; Douglas P Clark; Qing Kay Li
Journal:  Cancer Cytopathol       Date:  2010-10-25       Impact factor: 5.284

Review 9.  Glycoproteomics using fluid-based specimens in the discovery of lung cancer protein biomarkers: promise and challenge.

Authors:  Qing Kay Li; Ed Gabrielson; Frederic Askin; Daniel W Chan; Hui Zhang
Journal:  Proteomics Clin Appl       Date:  2013-01       Impact factor: 3.494

10.  Advances in fine needle aspiration cytology for the diagnosis of pulmonary carcinoma.

Authors:  Adnan Hasanovic; Natasha Rekhtman; Carlie S Sigel; Andre L Moreira
Journal:  Patholog Res Int       Date:  2011-06-27
View more
  13 in total

1.  Long-Term Cigarette Smoke Exposure and Changes in MiRNA Expression and Proteome in Non-Small-Cell Lung Cancer.

Authors:  Jayshree Advani; Yashwanth Subbannayya; Krishna Patel; Aafaque Ahmad Khan; Arun H Patil; Ankit P Jain; Hitendra S Solanki; Aneesha Radhakrishnan; Sneha M Pinto; Nandini A Sahasrabuddhe; Joji K Thomas; Premendu P Mathur; Bipin G Nair; Xiaofei Chang; T S Keshava Prasad; David Sidransky; Harsha Gowda; Aditi Chatterjee
Journal:  OMICS       Date:  2017-07

2.  Glycoprotein Enrichment Analytical Techniques: Advantages and Disadvantages.

Authors:  R Zhu; L Zacharias; K M Wooding; W Peng; Y Mechref
Journal:  Methods Enzymol       Date:  2017-01-16       Impact factor: 1.600

Review 3.  Defining glycoprotein cancer biomarkers by MS in conjunction with glycoprotein enrichment.

Authors:  Ehwang Song; Yehia Mechref
Journal:  Biomark Med       Date:  2015-09-02       Impact factor: 2.851

4.  Quantitative proteomic analysis reveals that anti-cancer effects of selenium-binding protein 1 in vivo are associated with metabolic pathways.

Authors:  Qi Ying; Emmanuel Ansong; Alan M Diamond; Zhaoxin Lu; Wancai Yang; Xiaomei Bie
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

5.  Aberrant Mucin5B expression in lung adenocarcinomas detected by iTRAQ labeling quantitative proteomics and immunohistochemistry.

Authors:  Yan Li; Xiangchun Wang; Minghui Ao; Edward Gabrielson; Frederic Askin; Hui Zhang; Qing Kay Li
Journal:  Clin Proteomics       Date:  2013-11-01       Impact factor: 3.988

6.  Updates and controversies in the rapidly evolving field of lung cancer screening, early detection, and chemoprevention.

Authors:  Hasmeena Kathuria; Yaron Gesthalter; Avrum Spira; Jerome S Brody; Katrina Steiling
Journal:  Cancers (Basel)       Date:  2014-05-16       Impact factor: 6.639

7.  LC-MS/MS quantitation of esophagus disease blood serum glycoproteins by enrichment with hydrazide chemistry and lectin affinity chromatography.

Authors:  Ehwang Song; Rui Zhu; Zane T Hammoud; Yehia Mechref
Journal:  J Proteome Res       Date:  2014-08-27       Impact factor: 4.466

8.  Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.

Authors:  Daniel Ajona; Cristina Razquin; Maria Dolores Pastor; Maria Jose Pajares; Javier Garcia; Felipe Cardenal; Michael Fleischhacker; Maria Dolores Lozano; Javier J Zulueta; Bernd Schmidt; Ernest Nadal; Luis Paz-Ares; Luis M Montuenga; Ruben Pio
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

9.  Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells.

Authors:  David J Clark; Yuping Mei; Shisheng Sun; Hui Zhang; Austin J Yang; Li Mao
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

10.  Mass spectrometry-based analysis of glycoproteins and its clinical applications in cancer biomarker discovery.

Authors:  Huan Liu; Ningbo Zhang; Debin Wan; Meng Cui; Zhiqiang Liu; Shuying Liu
Journal:  Clin Proteomics       Date:  2014-04-10       Impact factor: 3.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.